Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bittium Wearable Platform with Philips EmoGraphy & CardioSense Solution Was Awarded in the GSK’s “Transform the Future of Self-Care” Innovation Contest

Press release Free for release on July 1, 2019 at 10.30 am (CEST +1) Bittium Wearable Platform with Philips EmoGraphy & CardioSense Solution Was Awarded in the GSK’s “Transform the Future of Self-Care” Innovation Contest Oulu, Finland, July 1, 2019 – Bittium Wearable Platform with Philips EmoGraphy & CardioSense solution has been awarded as one of the five winners in the innovation contest “Transform the future of Self-Care ”, organized by the GlaxoSmithKline (GSK) Consumer Healthcare. In the winning solution Bittium

Kesko has completed the acquisition of the Volkswagen, Audi and SEAT businesses of Laakkonen Group

Kesko Group company K Caara Oy has completed the acquisition of the Volkswagen, Audi and SEAT businesses of Laakkonen Group. The transaction comprises Laakkonen Group’s Volkswagen, Audi and SEAT businesses in Hyvinkää, Hämeenlinna, Joensuu, Kuopio, Lahti and Tampere. The combined pro forma net sales of the businesses acquired totalled some €259 million in 2018 and operating profit €5.4 million. The approximately 460 employees of the acquired businesses will transfer toK-Caara and the business operations will continue to lease their current premises. The parties do not disclose the

Nixu signs a new 2,1 M€ cybersecurity partnership agreement with an industrial client

Nixu CorporationPress release 1.7.2019 at 10.25 EESTEuropean cybersecurity company Nixu announced that it has signed a contract for cybersecurity partnership with a globally operating industrial client. The contract now signed between the parties has an estimated total value of 2,1 million euros until the end of 2020.The contract includes a wide selection of Nixu’s holistic cybersecurity services. The services range from advisory and awareness services into ethical hacking and also include managing of digital identities. The goal of the services is to increase the resilience against

A Society continues to expand

A Society appoints Shahid Dar as Head of International Recruiting. A Society continues to expand its team to manage accelerated global growth.A Society, the leading services provider in the R&D and IT/ICT sourcing ecosystem today announced the appointment of Shahid Dar  as Head of International Recruiting. In this newly created role, Dar will be responsible for developing an international network of business partners and independent technology resources to expand A Society’s global sourcing capabilities. “We are thrilled to welcome Shahid Dar to A

ExpreS2ion licenses groundbreaking CRISPR/Cas9 gene editing technology from ERS Genomics

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the signing of a non-exclusive license agreement with ERS Genomics, providing ExpreS2ion with the right to use and commercialise products, for its own use or together with customers or partners, based on the highly efficient CRISPR/Cas9 gene editing technology. This will enable the Company to offer a whole new range of solutions for the next generation of vaccines, immunotherapy and diagnostics.The CRISPR/Cas9 gene editing technology was derived from a natural defence mechanism found in bacteria, and in recent years it has created a

Epiroc Q2 report and invitation to conference call on July 18

Stockholm, Sweden: Epiroc AB, a leading productivity partner for the mining and infrastructure industries, will publish its Q2 2019 results on Thursday July 18, at approximately 12:00 CEST. A combined presentation and conference call for investors, analysts and media will be held at 14:00 CEST.The presentation will be held in Epiroc’s office, Sickla Industriväg 19, Nacka, Sweden. The report will be presented by President and CEO Per Lindberg and CFO Anders Lindén. The presentation will begin with a short presentation of the report followed by a question-and-answer session. The

Trading in Adapteo Plc’s shares on the Main Market of Nasdaq Stockholm AB begins today

:dapteo Plc Regulatory Press Release 1 July 2019 at 08:30 am CEST  Trading in Adapteo Plc’s (“Adapteo”) shares on the Main Market of Nasdaq Stockholm AB begins today, 1 July 2019. The trading code of the shares in Adapteo is ADAPT. On 17 June 2019, the Extraordinary General Meeting of Cramo Plc (“Cramo”) decided that Cramo will demerge through a partial demerger (“Demerger”) so that all of the assets, debts and liabilities belonging to Cramo’s Modular Space business are transferred without a liquidation procedure to Adapteo. The completion of the Demerger was registered with the

Atlas Copco’s Q2 report 2019 and invitation to the conference call, July 15

Stockholm, Sweden, July 1, 2019: Atlas Copco will publish its Q2 results for 2019 on Monday, July 15, at approximately 12:00 AM CEST. A conference call for investors, analysts and media will be held at 2:00 PM CEST.Participating from Atlas Copco will be Mats Rahmström, President and CEO, and Hans Ola Meyer, CFO. The conference call will begin with a short presentation of the report followed by a question-and-answer session. The conference call will be broadcasted live on the web. Please see our website www.atlascopcogroup.com/investor-relations for the webcast link and presentation

Tobii welcomes Anand Srivatsa, new Division CEO of Tobii Tech

Tobii AB (publ) is pleased to announce that Anand Srivatsa is joining Tobii as the new Division CEO of Tobii Tech. Anand will lead Tobii’s efforts to grow a large and successful business providing eye-tracking technology to consumer devices and other volume products. Anand Srivatsa brings 15 years of experience from Intel Corporation where he most recently was Vice President in the Client Computing Group and General Manager of Intel’s Desktop, Systems and Channel Groups. Prior to this, he held various senior positions in Intel within sales and marketing in the United States and Taiwan,

Höegh LNG : Mandatory notification of trade

Hamilton, Bermuda, 1 July 2019 -  Höegh LNG Holdings Ltd. ("Höegh LNG", ticker "HLNG") advises that Richard Tyrrell, Chief Development Officer and primary insider, on Friday 28 June 2019 sold 8,941 common units in Höegh LNG Partners LP (“HMLP”) and his related party Rachel Brask- Tyrrell sold 1,059 common units in HMLP, both at a unit price of USD 17.30. Following the above transactions, Richard Tyrrell owns 9,215 shares and 24,400 Stock Options in Höegh LNG and 21,751 Phantom Units in HMLP. Rachel Brask- Tyrrell owns 3,067 common units in HMLP. * * * About Höegh LNG: Höegh LNG

STENOCARE enters the Irish market with its own subsidiary

STENOCARE A/S (“STENOCARE”) today announces that the company is entering Ireland with its new wholly owned Irish subsidiary, STENOCARE Ireland Ltd. The company is currently supplying medical cannabis products to the Danish market and will now start the process of having its medical cannabis oil Drops and vegan medical cannabis capsules approved by the Irish Health Products Regulatory Authority (HPRA). The timetable for the approval process is not stated yet. With approved products STENOCARE will offer Irish patients access to products with THC, CBD and a mixture of THC/CBD with the vision of

Redeye initiates coverage of AroCell

We initiate coverage of AroCell, a diagnostics company that focuses on the research, development and sales of an in vitro diagnostics product for cancer, called TK 210 ELISA, and the licensing of the technology behind this. After several years focusing on research and development, AroCell is now switching over to a commercial focus with itsTK 1 technology for cancer therapy response analysis. We see several potential catalysts in the short- and mid-term that are positive for the stock. Read more and download the research update: http://bit.ly/2Jevv6g Start following companies at

Photocure and Asieris enter into a global licensing deal for Cevira® with up to USD 250 million in milestones and double-digit royalties

Oslo, Norway July 1, 2019: Photocure ASA (Photocure, PHO: OSE), today announced that it has entered into a License Agreement providing Asieris Meditech Co., Ltd (Asieris) with a world-wide license to develop and commercialize Cevira® for the treatment of HPV induced cervical precancerous lesions. Under the agreement, Photocure will receive signing fees, development- and approval milestones, in addition to sales royalties.“We are proud to announce this agreement with Asieris, providing a global roadmap for the development and commercialization of Cevira. Cevira has the potential to be

Fasenra receives positive EU CHMP opinion for self

1 July 2019 07:00 BST Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector AstraZeneca today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to add a self-administration option for Fasenra (benralizumab) and a new delivery method as a pre-filled, single-use auto-injector (the Fasenra pen) to the medicine's product information in the European Union. The CHMP opinion can be implemented without the need for a European

Flexion appoints ABG Sundal Collier as its liquidity provider

Flexion Mobile Plc (Nasdaq: FLEXM) , the London-based Android games distribution company is pleased to announce that is has appointed ABG Sundal Collier as liquidity providers for the Flexion share. The commitment is carried out within the framework of Nasdaq First North's regulations on liquidity providers and means that the liquidity provider will quote bid and offer prices corresponding to a volume of at least SEK 15,000 with a maximum spread of 4 % between bid and offer price. The purpose is to promote the share's liquidity and the commitment begins on July

Finland’s EU Presidency has commenced – Business Finland highlights innovation, research and development

Finland's EU Presidency begins today, 1 July 2019. The forthcoming term offers Finns a window to Europe and an excellent opportunity to contribute to the future comptitiveness of the EU and Finland, sustainable growth, and investments into research and development. Business Finland will showcase Finland’s pioneering innovations and motivate different organizations to utilize the EU’s financial flows.In addition to official meetings, a wide range of events will be held in Finland during the EU Presidency, providing excellent opportunities for strengthening European cooperation and supporting

Eleda Group acquires Salboheds Bygg & Anläggningstjänst

Eleda Group has acquired all the shares in Salboheds Bygg & Anläggningstjänst AB, which performs traditional civil engineering works in Västerås and the surrounding area. The company, which have about 50 employees and annual sales of approximately SEK 400 million, combines civil engineering works within logistics and data with a stable order intake from public assignments. The company will form a fourth regional company within Eleda Group alongside Akeab, KEWAB and Mark & Energibyggarna. The company’s current Managing Director, Dennis Peters, continues in his current role onwards, and will

Forxiga receives positive EU CHMP opinion forDECLARE-TIMI 58 cardiovascular outcomes data

1 July 2019 07:00 BST Forxiga receives positive EU CHMP opinion for DECLARE-TIMI 58 cardiovascular outcomes data AstraZeneca today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the European marketing authorisation for Forxiga (dapagliflozin) in patients with type-2 diabetes (T2D) to include cardiovascular (CV) outcomes data from the Phase III DECLARE-TIMI 58 trial. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: "We are pleased with this positive opinion for the cardiovascular

OKEA ASA – Acceleration of exploration around Draugen Hub

OKEA ASA and partners Petoro AS and Neptune Energy Norge AS, have agreed to continue exploration licence PL958, east of the OKEA-operated Draugen field, six months after OKEA assumed operatorshipOKEA ASA and partners Petoro AS and Neptune Energy Norge AS, have agreed to continue exploration licence PL958, east of the OKEA-operated Draugen field, six months after OKEA assumed operatorship. This commits the licence partners to acquire new 3D seismic data and they have already decided to prefund a 3D seismic multi-client acquisition by PGS ASA, starting up in July 2019. “We are excited to

Buy-backs of shares of series B in Saab during week 26 2019

During the period 24 June – 28 June 2019, Saab AB (publ) (LEI code 549300ZHO4JCQQI13M69) has repurchased in total 329.000 own shares of series B (ISIN: SE0000112385) as part of the share buy-back programme initiated by the Board of Directors in order to secure delivery of shares to participants in Saab’s long-term Share Matching Plan, Performance Share Plan and Special Projects Incentive.The share buy-back programme, which Saab announced on 5 June 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the Commission Delegated Regulation (EU)

NCC to build 225 apartments in Linköping for Riksbyggen

Together with Riksbyggen, NCC will build eight new apartment blocks with a total of 182 rental units and 43 tenant-owner apartments in Berga Park, Linköping. The order is worth SEK 290 million.“Linköping is growing and we are now building a total of eight new apartment blocks in the Berga Park. There is demand for small and large apartments, both to rent and to buy, in the city and we have therefore chosen to build a corresponding mix in the same district to try to meet as many of these needs as possible,” says Mårten Lilja, vice president at Riksbyggen and Head of business area

FarmPharma starts the project at Testa Center

FarmPharma AB, which is subsidiary to Double Bond Pharmaceutical AB, has today started the project at Testa Center as a part of cooperation agreement with GE Healthcare in Uppsala. As previously announced , FarmPharma has been granted financial means for this project within the framework of the "BioProcess Innovation Center" from Vinnova. The work is expected to last for one week in July and two weeks in August. The purpose of the project is to test the manufacturing procedure of InterferOX components on a

LeoVegas granted gaming licence in Spain

LeoVegas has been granted a gaming license in Spain and will launch the Spanish site shortly. The gaming license applies to both Casino and Sports games."We welcome Spain as our 7th locally regulated market. With LeoVegas position as "King of Casino" we are now entering Spain with the ambition to take the mobile position and offer the ultimate gaming experience. The Spanish online gambling market have a strong underlying growth with over 20% per year. The Spanish license is an important step in our continued expansion, in other Spanish-speaking where we have already conducted test launches

Herantis Pharma publishes newsletter for May-June

Herantis Pharma publishes newsletter for May-June Herantis Pharma PlcPress release 1 July 2019 at 9:00 am Herantis Pharma plc (“Herantis”) has published its newsletter for May-June 2019. The newsletter is also attached to this press release. Herantis’ newsletter is published every other month on the company’s web site . It is also available by email subscription . Further information: Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445Company web site: www.herantis.com About Herantis

There are no items matching the current filter
There are no more items matching the current filter
Back to top